Analytical (technologies & services)

Nordic Life Science Days

Cell selection algorithm turns medical waste into treatment

27-Sep-2019 By Vassia Barba

NextCell’s development platform enables the selection of specific stem cells in order to create a treatment with various potential indications.

TrakCel and McKesson to build supply service for late-stage cell therapies

19-Sep-2019 By Vassia Barba

McKesson partners with TrakCel aiming to address the supply chain challenges of cell and gene therapy developers in late stages of development or approaching commercialization.

Future of diabetes care will be about data

18-Sep-2019 By Vassia Barba

Insulin dosing and glucose level monitoring data combined in one platform is the object of two major partnerships focusing on diabetes.

Pharma takes interest in genomics to next level

16-Sep-2019 By Ben Hargreaves

Four pharma companies are providing half of the investment required for ‘world’s largest genetics project’, in return for access to the genomic data generated.

Genome editing allows for ‘faster, simpler’ CHO cell lines

03-Sep-2019 By Ben Hargreaves

As MilliporeSigma expands its patent portfolio for its genome editing technology, the company’s head of strategy discusses how CRISPR is changing the bioproduction landscape.

Sterling begins large-scale silica production for Nanologica

29-Aug-2019 By Vassia Barba

Sterling begins manufacturing of $14m worth of silica particles as preparative chromatography media, after deal with Chinese distributor.

UK launches fund for commercial manufacture of advanced therapies

28-Aug-2019 By Ben Hargreaves

UK government invests further in businesses manufacturing advanced therapies, opening a fund for companies working on technology to improve commercial production.

Supply chain to supply ‘cycle’: TrakCel CEO talks cell and gene therapies tracking

14-Aug-2019 By Vassia Barba

The increasing number of cell and gene therapies in clinical development is evolving the supply chain into a ‘supply cycle,’ says TrakCel CEO, with service providers being called to maintain control under pressure.

Genomic data on cancer treatment released to public

02-Aug-2019 By Ben Hargreaves

New data on the genetic biomarkers impacting the development of cancer treatments has been released creating the largest publicly accessible dataset of its kind.

Emergex develops synthetic hand-foot-and-mouth vaccine

10-Jul-2019 By Vassia Barba

In collaboration with a research center, Emergex will apply its synthetic development approach on a vaccine against hand, foot and mouth disease.

Working against the ‘hard’ vaccines with patient capital

08-Jul-2019 By Vassia Barba

Vaccine research is still quite ‘empirical’ and there is a long way until it is turned into a rational, predictable modality, suggests director at the Bill and Melinda Gates Foundation.

Fujifilm plots third cell culture facility in Netherlands

02-Jul-2019 By Ben Hargreaves

Fujifilm announces plans to open its third manufacturing facility for cell culture media, joining existing facilities in the US and Japan.

United Cargo in deal to lease and transport SkyCell’s containers

01-Jul-2019 By Vassia Barba

United Cargo includes SkyCell’s temperature-controlled containers in its ‘rapidly increasing’ TempControl transport service for biopharmaceuticals.

Be The Match and TrakCel partner on integrated services for cell therapy developers

24-Jun-2019 By Vassia Barba

Be The Match BioTherapies and TrakCel form a strategic partnership to integrate their offering for companies developing cell and gene therapies.

Cognizant acquires Zenith to become single source provider

18-Jun-2019 By Maggie Lynch

Zenith-Cognizant Technologies emerges from an acquisition aimed to streamline solutions as more complex “smart factories” become a greater focus in the biopharmaceutical industry.

Savsu to supply Novartis’ newly-approved SMA treatment

06-Jun-2019 By Vassia Barba

Novartis to continue with AveXis’ adoption of Savsu’s evo cold chain management technology for newly-approved gene therapy.

How to solve the cell and gene therapy skill gap?

03-Jun-2019 By Ben Hargreaves

In the UK alone, the numbers of employees entering the cell and gene therapy manufacturing space needs to double in the next five years, eXmoor’s MD suggested.

Iovance builds gene therapy manufacturing facility in Philadelphia

30-May-2019 By Maggie Lynch

Iovance amps up clinical and commercial immunotherapy production with a $75m (€67.3m), 136,000 square-foot build in Philadelphia’s Navy Yard.

Harbour BioMed inks agreement for ‘next generation biologic discovery’

30-May-2019 By Maggie Lynch

Harbour BioMed and an unnamed ‘leader’ in immunology enter license agreement to develop, discover, and commercialize biologic therapeutics using the former’s transgenic mouse platform.

Cel-Sci’s arthritis vaccine ‘reprogramming’ the immune system

29-May-2019 By Vassia Barba

Cel-Sci’s rheumatoid arthritis treatment, developed under an $1.5m NIH grant, will be featured at the BIO Convention in Philadelphia next week.

Rexgenero extends European reach with expanded manufacturing

29-May-2019 By Maggie Lynch

Partnership with German Red Cross will see Rexgenero’s lead drug candidate reaching broader patient base in clinical trials.

SGS’ Glasgow biosafety facility doubles in size

28-May-2019 By Maggie Lynch

SGS’ completed the ₤8.7m expansion of its large molecule testing facility in Glasgow and made room to increase its existing biosafety service and PCR platform capabilities.

Lonza adopts Synpromics’ inducible promoters, expands bio manufacturing platform

22-May-2019 By Vassia Barba

Lonza and Synpromics move on to the commercialization of a number of inducible promoters to expand the former’s manufacturing offerings.

Genentech and Parvus develop autoimmune therapies in collaboration

22-May-2019 By Maggie Lynch

Genentech will collaborate with biopharma company Parvus to manufacture and commercialize Navacim therapeutics for the treatment of autoimmune disease.

Small businesses the ‘bedrock’ that allow for innovation

20-May-2019 By Ben Hargreaves

There are 1,500 SME medicine discovery companies in the UK and more than half are working on non-small molecule therapeutics, a Catapult report finds.

Immunologix boosts Translational Sciences division with new recruits

13-May-2019 By Maggie Lynch

Immunologix bolsters its scientific expertise with two new hires to build on its bioanalytical biomarker programs created from the launch of its Translational Sciences division.

Marken launches container for cell and gene therapy shipment

15-Apr-2019 By Vassia Barba

Marken introduces a container for shipments of clinical drug products, clinical drug substance, as well as cell and gene therapies.

Merck extends research agreement for NASH drug candidate

27-Mar-2019 By Maggie Lynch

Merck exercises its option to extend research phase with NGM for an additional two-year period, moving the collaboration end date to March 2022.

Applications of nanotech may provide bioavailability

26-Mar-2019 By Maggie Lynch

Nanotechnology may be able to increase bioavailability in low-solubility drugs and improve a drug’s chance of success, according to Ascendia CEO.

ATS harnesses electromagnetic technology for cell minimizing unit

21-Feb-2019 By Maggie Lynch

ATS’ SuperTrak Micro minimizes cell sizes through electromagnetic sorting while merging and diverting at full production speed.

Human genome editing committee created after industry calls for standards

20-Feb-2019 By Maggie Lynch

The WHO establishes a multi-disciplinary committee to advise on the ethical and scientific challenges of human genome editing, as the technology’s capability and utilization grows in the industry.

Four-pronged partnership to produce automated systems for CRISPR

20-Feb-2019 By Maggie Lynch

Oxford Genetics and Sphere Fluidics to partner, alongside additional biopharma organizations, to develop automated systems for high-throughput gene editing in mammalian cell lines.

Biotech licenses protein production tech to Eli Lilly

13-Feb-2019 By Maggie Lynch

ProteoNic licenses its 2G UNic technology to Eli Lilly for the development of the latter’s proprietary products.

AbbVie enters $90m agreement to develop multiple myeloma immunotherapy

12-Feb-2019 By Maggie Lynch

AbbVie and Teneobio enter an agreement to develop and commercialize an immunotherapeutic for the treatment of multiple myeloma using the latter’s proprietary anti-CD3 platform.

Amgen enters licensing agreement to use oral formulation platform

18-Dec-2018 By Maggie Lynch

Entera will use its proprietary drug delivery platform to progress Amgen’s preclinical programs into oral formulations.

Cambrex continues build-out at former PharmaCore site with $1m investment

11-Dec-2018 By Melissa Fassbender

Cambrex is investing $1m at its High Point, NC-based site, marking the most recent in a series of investments which will see the addition of 1,300 square feet and 15 new employees.

Tech focus: Making waves with acoustic separation in cell processing

06-Dec-2018 By Ben Hargreaves

FloDesign Sonics is using ‘acoustophoresis’ to address challenges in cell therapy manufacture.

UK-funded study to investigate patients’ experience of cell and gene therapies

05-Dec-2018 By Flora Southey

Innovate UK is helping to fund the PROmics study, a programme designed to assess the effect of cell therapies on patient symptoms and quality of life.

Q&A

Biologics delivery tech could accelerate wound healing by 80%, says Ilya Pharma

03-Dec-2018 By Flora Southey

The Swedish biotech’s lead candidate, ILP-100, is designed to continuously deliver biological drugs to the wound surface for approximately one hour.

Brammer Bio advancing 3 year, $200m program: 700 employees expected by mid-2019

27-Sep-2018 By Melissa Fassbender

Brammer Bio’s three-year, $200m investment program is set to establish more than 30 suites for both clinical and commercial viral vector supply.

Inside the Testa Bioprocess Innovation Center

26-Sep-2018 By Flora Southey

Biopharma-Reporter takes you inside the recently opened Testa BioProcess Innovation Center in Uppsala, Sweden, and speaks with CEO of GE Nordics, Lotta Ljungqvist.

Thermo and Oxford Genetics expand CRISPR toolkits with ERS deals

25-Sep-2018 By Ben Hargreaves

Thermo Fisher and Oxford Genetics have announced separate plans to partner with ERS Genomics, gaining access to CRISPR gene editing technology.

How the US-Mexico trade deal could impact the biologics market

17-Sep-2018 By Ben Hargreaves

BioPharma-Reporter (BPR) discusses with Jennifer Fox (JF), co-chair of Brinks Gilson & Lione’s biopharma practice group, the provisional detail revealed from the US administration’s proposed trade deal with Mexico, and its potential impact on the...

ABL Bio and I-Mab Biopharma ink bispecific antibody deal

14-Aug-2018 By Maggie Lynch

ABL Bio and I-Mab Biopharma have partnered to develop bispecific antibodies for immunotherapy.

GE looks to speed drug discovery with new high capacity system

19-Jun-2018 By Melissa Fassbender

GE has introduced a new high capacity system designed to improve productivity in the increasingly complex drug discovery process.

Crescendo Biologics out-licenses 'Humabody' asset to Zai Lab

30-May-2018 By Melissa Fassbender

Zai Lab and Crescendo Biologics have signed a licensing agreement under which Zai Lab will develop protein therapeutics for inflammatory indications.

Personalized medicine driving biobanking demand, says sample management provider

29-May-2018 By Melissa Fassbender

The growing emphasis on personalized medicine is driving the need for biobanking services – demand for which is expected to continue increasing.

UK invests in cell and gene therapy workforce to prepare for commercial products

29-May-2018 By Nick Taylor

The UK is investing £3m ($4m) to build a workforce capable of delivering cell and gene therapies to patients at commercial scales.

The Golden Ticket: Sanofi, Meditope initiate research collaboration to explore bioconjugation tech

09-May-2018 By Melissa Fassbender

Sanofi has awarded Meditope Biosciences a BioLabs’ “Golden Ticket” to support the development of its bioconjugation platform and create new antibody-based therapeutic constructs.